Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 20, 2026 01:30 ET | Source: Synendos Therapeutics AG

Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder

Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder, marking the first time a SERI molecule is dosed in a patient population